Nisa Investment Advisors LLC Boosts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Nisa Investment Advisors LLC raised its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 495.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,304 shares of the company’s stock after purchasing an additional 2,749 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Pacira BioSciences were worth $62,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. CWM LLC raised its stake in shares of Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after acquiring an additional 5,716 shares during the period. Virtus Investment Advisers Inc. acquired a new stake in Pacira BioSciences in the 3rd quarter valued at $98,000. China Universal Asset Management Co. Ltd. raised its position in Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after purchasing an additional 3,404 shares during the period. Quest Partners LLC lifted its stake in shares of Pacira BioSciences by 137.6% during the third quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after purchasing an additional 5,449 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Pacira BioSciences in the third quarter worth about $191,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Price Performance

PCRX opened at $26.33 on Friday. The company has a market capitalization of $1.22 billion, a P/E ratio of -12.97 and a beta of 0.76. The company has a 50-day moving average of $20.06 and a 200-day moving average of $17.69. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $34.01.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PCRX shares. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the company from $8.00 to $25.00 in a report on Thursday. HC Wainwright reiterated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Barclays reduced their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Needham & Company LLC raised their price target on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $26.20.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.